Overview

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung squamous cell carcinoma has a better tumor response rate and safety, therefore.The main purpose of this study is to observe the safety and efficacy of albumin-bound paclitaxel / carboplatin in the treatment of lung squamous cell carcinoma of stage IIB and IIIA.

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Guangzhou Medical University

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel